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US-English speaking and 16 US-Spanish speaking participants
with primary or secondary insomnia. Data for the validation of
the SIS were collected alongside a North American 4-week multi-
center, double-blind, placebo-controlled, randomized, parallel-
group study in primary and secondary insomnia patients. Item
level analyses including assessment of missing data, item-item
correlations, Principal Components Analysis, and clinical valid-
ity were conducted. Items with ﬂoor or ceiling effects were can-
didates for deletion, as were items which did not load with any
particular domain. Once domains were determined, validity of
the domains was assessed through internal consistency reliability,
item-domain concurrent and divergent validity, clinical validity,
concurrent validity and conﬁrmatory factor analysis. Addition-
ally, responsiveness and minimal important difference estimates
were determined. RESULTS: Patient interviews resulted in
55 items in 8 domains. During item reduction and validation,
18 items were deleted based on their content validity, high
ceiling effect (>40%), redundancy (Inter-item Pearson correla-
tion > 00.80) no or multifactor loading and/or failure to meet the
Item-level discriminant validity criterion. After reduction, the
ﬁnal SIS consists of 35 items in 7 domains. CONCLUSION:
The SIS was developed to account for US-English and US-Spanish
cultural differences. The validation study provides evidence on
the psychometric properties of the SIS. The SIS has been shown
to adequately meet the criteria for a validated measure to be used
in clinical trials.
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OBJECTIVES: To comprehensively explore existing quality of
life (QoL) measures in alcoholism (alcohol abuse and alcohol
dependence). METHODS: Systematic searches of Scopus (1990–
2007) were conducted using terms synonymous with alcoholism
combined with terms associated with measuring QoL. RESULTS:
In total, 618 abstracts were identiﬁed detailing the use of 16
generic patient-reported measures to assess QoL in alcoholism.
Upon further examination (ie searching Scopus using the QoL
measure as a search term from date of development) nine mea-
sured health status and seven assessed generic QoL, with varying
deﬁnitional criteria and domain focus. The SF-36 and EQ-5D, in
particular, have been used widely but frequently misinterpreted
as measures of QoL rather than health status. One alcohol-
speciﬁc QoL measure was identiﬁed; the AlQoL 9, a scale that
the authors have claimed to epitomise alcohol-related QoL.
However, the AlQoL 9 was developed by reducing the SF-36
(French version) to the nine items most relevant to alcoholism.
The methodology for determining the relevance of the existing
items of the SF-36 was comprehensive but the adapted measure
does not include assessment of additional concepts (such as sleep
and social isolation) of particular importance for alcohol-related
QoL. CONCLUSION: There is a lack of research and assessment
of QoL in alcoholism. Individuals need to be given the opportu-
nity to determine the extent to which their QoL is impaired by
alcoholism based upon their own criteria for what constitutes
good QoL. There is a need for an alcoholism-speciﬁc QoL
measure, which focuses on the domains that are most salient to
people with such problems. Furthermore, research that includes
an assessment of the impact of alcoholism on the QoL of friends,
family and colleagues of the person abusing alcohol would also
be valuable. Only then will we be able to assess the full impact of
alcoholism (and its treatment) on QoL.
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OBJECTIVES: Caregivers’s patients with Alzheimer’s disease
(AD) experience physical and psychical stress due to the caring.
This study evaluated the beneﬁts of a Psychosocial Intervention
Program (PIP) on caregivers’ burden METHODS: A epidemio-
logical, prospective, randomized, multicenter study was con-
ducted by psychiatrists who recruited 115 primary caregivers’s of
patients with AD (DMS-IV criteria and MMSE score = 10–26)
and at least 2 impaired instrumental activities of daily living
(IADL score) by Lawton & Brody Test. Caregivers were random-
ized to receive either PIP (intervention group (IG), n = 60) or
standard care (control group (CG), n = 55). PIP consisted on
individual sessions (scheduled every 1–2 weeks during 4 months)
of teaching strategies to reduce caregiver burnout. Caregivers
stress, quality of life (QoL) and perceived health were measured
using validated scales (Zarit, SF-36, GHQ-28) at baseline, after a
4-month and a 10-month follow-up period RESULTS: The
proﬁle of patient with AD was a 77-years-old woman, with
moderate dementia (MMSEscore = 18.74) and high impairment
of daily living activities (mean IADLscore = 2.17). The caregiver
proﬁle was a 60-years-old woman, wife or adult daughter, who is
being careing for 3 years and care daily time was >12 hours,
without refund. Changes in caregiver burden (baseline
Zaritscore–ﬁnal Zaritscore) showed an improvement in the IG
(-8.09 points) and a worsening grouping the CG (+2.08 points),
with statistically signiﬁcance (p = 0.0083). The IG showed sig-
niﬁcant improvements in all the well-being perception areas mea-
sured by the SF-36scores and signiﬁcantly lower score in the
GHQ-28score (p = 0.0004). Caregivers and therapists consid-
ered PIP “useful/very useful” in a 97.7% and 88.6% respectively
at the end of PIP, and in a 93.2% and 86.3% at 6 moths after PIP
ending. CONCLUSION: Caregivers’ psychosocial training can
minimize caregiver distress and may help to develop strategies for
coping problems. PIP improves QoL and the perceived health of
caregivers of patients with AD.
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OBJECTIVES: Insomnia is frequently associated with general-
ized anxiety disorder (GAD) and affects the patient’s day to day
life. The Sleep Impact Scale (SIS) was developed to assess the
impact of insomnia; however it has not been used in GAD.
Therefore, a study was conducted to validate the SIS and evaluate
the impact of zolpidem tartrate extended-release on insomnia in
GAD. METHODS: Validation and efﬁcacy data of the SIS were
collected alongside a randomized, placebo-controlled trial of
escitalopram + placebo or zolpidem tartrate extended-release in
adults with insomnia associated with GAD. The validation con-
sisted of evaluation of the validity and reliability, the responsive-
ness and the MID of the SIS domains to ensure the questionnaire
was acceptable in a GAD population. The efﬁcacy analysis was
performed on the ITT population, consisting of general linear
models to evaluate changes from baseline at each timepoint, with
study endpoint as the primary change score analysis. Longitudi-
nal analyses were also performed to evaluate the effects of
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treatment through time using repeated measures ANCOVA.
RESULTS: The SIS was found to meet psychometric standards
for a valid questionnaire in a GAD population. The efﬁcacy
analysis found four domains (Daily Activities, Emotional Impact,
Energy/Fatigue and Satisfaction with Sleep) consistently demon-
strated signiﬁcantly greater improvements in the zolpidem tar-
trate extended-release group at each timepoint. A quick onset of
treatment effect was evident in all domains of the SIS by Week 2,
with all domains statistically signiﬁcantly demonstrating greater
improvement than placebo. Longitudinal analyses found all SIS
domains to be statistically signiﬁcantly superior to placebo.
CONCLUSION: The SIS adequately meets the criteria for a
validated measure to be used in GAD. The SIS was responsive to
treatment effects in this clinical trial and able to demonstrate
improvements in patient reported outcomes, favoring zolpidem
tartrate extended-release.
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OBJECTIVES: Prior to use in an international study, the Hos-
pital Anxiety and Depression Scale (HADS) underwent linguis-
tic validation in 30 languages. The original scale was developed
in UK English to detect states of anxiety and depression in and
outside hospital and also community settings. A rigorous meth-
odology was required to ensure conceptual equivalence and cul-
tural relevance across different languages. METHODS: The
translation process was conducted by a specialist in each target
country using the following standardized methodology: 1) two
forward translations by professional translators who were
native speakers of the target language and ﬂuent in English; 2)
comparison and reconciliation of the translations by the spe-
cialist in the target country; 3) backward translation by a
native English speaker; 4) comparison of source and backward
version; and 5) review by the developer. The linguistic valida-
tion methodology for some languages deviated slightly from
what is described above, as a translation already existed; the
translation process started at the backward translation step on
the existing version. RESULTS: The translation process
revealed linguistic and conceptual challenges. Translating idi-
omatic expressions often required paraphrasing to convey the
intended meaning whenever a literal equivalent was not con-
ceptually equivalent and culturally relevant. In addition, while
in most language versions it was possible to retain the same
tense as in the original instrument without alteration of
meaning in a few translations it proved necessary to use a dif-
ferent tense to achieve clarity and equivalence of concept.
CONCLUSION: The language versions of the HADS were
established according to a rigorous translation methodology.
The process aims to ensure conceptual equivalence across dif-
ferent language versions to facilitate international comparison
and pooling of data. The linguistic validation process as
a whole supports the advantage of integrating international
feedback on concepts and wording before a questionnaire is
ﬁnalized.
PMH60
A PHARMACOECONOMIC COMPARISON OF ESCITALOPRAM
AND DULOXETINE INTREATMENT OF MAJOR DEPRESSIVE
DISORDER (MDD) INTHE UNITED KINGDOM
Wade AG1, Fernandez JL2, François C3, Hansen K3, Despiegel N3,
Danchenko N3
1CPS Research, Glasgow, UK, 2London School of Economics, London,
UK, 3H. Lundbeck A/S, Paris, France
OBJECTIVES: To evaluate cost-effectiveness of escitalopram
vs. duloxetine in MDD and to identify key drivers of costs in
treatment of depression with escitalopram and duloxetine.
METHODS: An economic evaluation was conducted alongside a
double-blind, randomized study (escitalopram 20 mg/day and
duloxetine 60 mg/day) in outpatients with MDD, aged 18–65
years, with Montgomery Asberg Depression Rating Scale
(MADRS) 26 and Clinical Global Impression Severity (CGI-S)
4, and with reported baseline duration of depressive episode of
12 weeks-1 year. The main cost-effectiveness (CEA) analysis was
conducted on the full analysis set (FAS), with all patients having
1 valid post-baseline health economic assessment. Additional
analyses were conducted on completers set (CS) with complete
follow-up data. Outcomes included Sheehan Disability Scale
(SDS), MADRS total score, treatment response (MADRS
decrease 50%) and remission (MADRS12), and health care
resource use and absenteeism from work evaluated by Health
Economic Assessment. Unit costs of health care services were
obtained from UK published standard sources. RESULTS: In the
main CEA analysis on FAS, escitalopram appears to be more
effective on the SDS scale (95% CI 0.10–3.74) and less costly
than duloxetine (95% CI -1.544 to -247). In additional analy-
ses on CS, patients on escitalopram had 49% lower total cost
compared to duloxetine (p = 0.002), with sick leave contributing
>73% of the total disease cost. Escitalopram was associated with
58% shorter sick leave duration compared to duloxetine
(p < 0.001). Patients with treatment response had 46% shorter
sick leave (p = 0.008), and those achieving remission, sick leave
was 53% shorter (0.002). CONCLUSION: Escitalopram domi-
nates duloxetine on the SDS scale, and is associated with signiﬁ-
cant cost savings compared to duloxetine. Treatment with
escitalopram may reduce sick leaves duration through improved
treatment response, and result in cost savings compared to
duloxetine. The results are in line with other economic studies
showing cost-saving with escitalopram compared to venlafaxine,
another SNRI.
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OBJECTIVES: Primary pulmonary hypertension (PPH) is a dis-
order with limited treatment options. Sildenaﬁl, an oral phos-
phodiestrase type-5 (PD-5) inhibitor and a pulmonary vasodilator,
is likely to be beneﬁcial in patients with primary pulmonary
hypertension,. we hypothesized that a single dose of Sildenaﬁl
could acutely reduce peak pulmonary artery pressure and improve
echocardiographic diameters of right heart. METHODS: We
studied 12 consecutive patients with PPH (10 patients with New
York Heart Association functional class 222, and 2 patients with
functional class22). After initial echocardiographic evaluation, a
100 mg oral single dose of Sildenaﬁl was added to previous
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